India is considering stronger regulatory data protection for new medicines. The country's generic pharmaceutical industry has warned that the move could delay affordable treatments, disrupt business models and alter the delicate balance between encouraging innovation and ensuring access to low-cost healthcare.
Companies in manufacturing say the tougher protection is necessary to enhance research and development. While domestic manufacturers fear it will undermine one of India's greatest competitive strengths - its world-leading generic medicines industry.
The debate has gathered momentum after the Organisation of Pharmaceutical Producers of India (OPPI) urged the Central Drugs Standard Control Organisation (CDSCO) to introduce a longer period of regulatory data protection, also known as data exclusivity, for novel medicines.
The proposal has reopened a long-running policy discussion over whether India should strengthen intellectual property-linked protections or preserve the regulatory framework that has enabled its generic pharmaceutical industry to flourish.
India is known as the pharma of the world, as nearly one-fifth of the world's generic medicines are produced in the country. With the country’s pharmaceutical exports becoming an important source of affordable medicines for patients in developing economies, any policy change impacting generic competition is significant not just for the domestic market but for global healthcare too.
Data Exclusivity Understanding
Regulatory data protection safeguards the clinical trial data submitted by innovator companies to obtain marketing approval for a new medicine, unlike patents, which protect a pharmaceutical invention. In India today, patent protection for medicines can expire, and generic manufacturers are seeking approval for equivalent medicines through well-established routes of approval backed by bioequivalence studies, which do not require large-scale clinical trials.
A stronger data exclusivity regime could alter that process by stopping generic manufacturers from using the innovator's clinical data for a certain period. Companies may have to wait until the exclusivity period ends or conduct costly clinical trials on their own, which could postpone the introduction of cheaper options.
According to Jeevan Kasara, Chairman, Steris Healthcare, such a move could fundamentally alter the economics of India's generic pharmaceutical industry.
"The introduction of strong data exclusivity provisions would delay the development of generic drugs by denying the generic developers access to clinical data of the innovator drugs on which the bioequivalence applications depend. The lack of this benchmark would force the firms to wait for the period of exclusivity to expire or to conduct their own costly studies, an expense that is beyond the means of small generic producers," Kasara said.
He added that the result would be fewer affordable generic medicines entering the market, particularly for newer therapies targeting cancer, autoimmune disorders and rare diseases.
The issue has also attracted attention from legal and regulatory experts. In a recent LinkedIn post, healthcare law specialist Rupal Rana Arya said a proposed 10-year regulatory data protection regime could effectively delay generic competition even after patent expiry, allowing innovator medicines to retain premium pricing for longer. Arya argued that while patents protect inventions, data exclusivity protects the investment behind clinical trial data, creating an additional regulatory barrier for generic manufacturers.
Impact on Patent and Business
The issue for Indian drug makers is not just regulation but long-term business sustainability. Generic manufacturers typically have product pipelines in place years before patents expire, so that they can launch medicines right after regulatory approval. Any additional exclusivity period may delay revenues, disrupt manufacturing plans and change investment decisions.
Kasara believes the commercial consequences would be particularly severe for smaller companies.
"In the case of India's generic manufacturers, data exclusivity would narrow down their margins, postpone their revenues from product launches, and unfairly discriminate against mid-sized and small companies that do not have the funds to conduct clinical trials independently," he said.
He added that multinational innovators would gain a competitive advantage, while India's generic industry – which employs lakhs of people and underpins the country's pharmaceutical exports – could face structural barriers affecting both domestic sales and export opportunities.
The implications extend beyond the corporate ledger. Historically, generic drugs have come to market shortly after patent expiry, providing competition and lowering costs of treatment. According to Kasara, a delay in generic entry would keep innovator medicines at higher prices for longer.
"The greatest way to reduce medicine costs in India is through generic competition. Whenever generics hit the market, there is a 60-80 per cent reduction in prices during the first year of competition. Delaying generic entry means originator prices continue for longer, placing the latest medicines beyond the reach of many Indian patients," he said.
The effect may be especially relevant in India, where medicines constitute a substantial part of cash outlays for health expenditure. Millions of chronic disease patients, such as those with diabetes, hypertension, cardiovascular disease and cancer, rely on affordable generic medicines for lifelong treatment. Government programs like Pradhan Mantri Bhartiya Janaushadhi Pariyojana and Ayushman Bharat also rely heavily on generic medicines priced competitively to ensure financial sustainability.
Intellectual property consultant Pankaj Kumar finds similar concerns, arguing that India's existing regulatory framework already balances innovation with public health objectives. He said that India's current approach aligns with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which requires protection of undisclosed test data against unfair commercial use but does not mandate data exclusivity.
While the generic industry has raised concerns, there is a collective agreement among stakeholders that fostering pharmaceutical innovation is essential for India to build its research ecosystem and move beyond manufacturing off-patent medicines.
The challenge of designing a framework that attracts greater pharmaceutical investment without chipping away at the generic medicines industry in India will remain, as policymakers consider stakeholder feedback. |
